EUREX: Eurex Equity Index News – January 2021
Eurex's global MSCI update: 96 percent market share in MSCI Asia underlying futures, 50 percent in MSCI derivatives globally
Eurex continues the success story of its MSCI segment in the December roll month and once again proves that it is the exchange of choice for trading Asia Pacific MSCI derivatives. After the recent roll, Eurex starts the first quarter holding more than 86 percent of global Open Interest in MSCI derivatives on Asian underlyings, compared to 47 percent at the end of 2019. Overall, Eurex holds 50 percent market share globally in MSCI related derivatives. Read full press release here.
How evolving ESG indices & derivatives help transforming portfolios
The Covid-19 pandemic has accelerated the move towards sustainable investments as global investors were already shifting away from existing benchmarks to sustainable alternatives. On top of this are regulatory drivers such as the EU’s Action Plan on Sustainable Finance and Green Deal. Part of this ‘new normal’ is the emergence of derivatives as a powerful tool to help ESG integration. Derivatives on ESG benchmarks offer a way to help facilitate ESG integration while offering a cost-efficient and liquid solution with a low tracking error close to benchmark performance. Read full article here.
Save the date: March 23-24 | Virtual edition of the Derivatives Forum Frankfurt 2021
The Derivatives Forum Frankfurt 2021 will be held as a virtual edition with thought leadership insights, industry debates, keynote speeches and virtual networking opportunities. The Derivatives Forum is the leading European event focused on trading and clearing for derivatives and securities financing across asset classes. Originally planned as a physical event in early March, the Derivatives Forum is set to be on March 23 and 24.
We are proud to have CNBC, DerivSource, IPE, Opalesque, Responsible Investor and Risk.net as our media sponsors and the BVI as a partner association. More info.
For more information, please contact Eugen Mohr or T (312) 544-1084.